Table 1. Clinical features, treatment, outcome in 6 patients with placental site trophoblastic tumor.
| Characteristic | Patient number | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| Age (yr) | 29 | 32 | 32 | 29 | 31 | 33 |
| AP | N/A | Term | Term | Term | Term | Term |
| Interval from AP (mon) | N/A | 6 | N/A | 3 | 10 | 12 |
| Presenting features | IVB | IVB | IVB | IVB | IVB | Amenorrhea |
| β-hCG at diagnosis (mIU/mL) | 171.0 | 32.0 | 0.4 | 35.9 | 2.6 | 903.5 |
| FIGO stage | I | I | I | I | I | I |
| Mets (No./site) | - | - | - | - | - | - |
| Myometrial invasion | Superficial | Deep | Superficial | Superficial | N/A | Deep |
| Mitotic index, (mitoses/0 HPF) | N/A | N/A | N/A | 8 | N/A | 4 |
| IHC | N/A | N/A | Ki-67 (5–10%), CK 8 & 18, CD 10 | Ki-67 (>10%) | Ki-67 (>10%), hCG | Ki-67 (20%), hPL, hCG, CK 7 |
| Dx procedure | D/E | D/C/B | D/C/B | D/C/B | D/C/B | Image |
| Surgery | TAH | TAH, RSO, LS, PLND | SPA-H, BS | TAH, ROC | LAVH | TAH, BS |
| Chemotherapy | - | - | - | - | - | - |
| Outcome | NED | NED | NED | NED | NED | NED |
| Follow-up (mon) | 2 | 84 | 46 | 73 | 48 | 1 |
AP, antecedent pregnancy; IVB, irregular vaginal bleeding; hCG, human chorionic gonadotropin; β-hCG, beta human chorionic gonadotropin; FIGO, International Federation of Gynecology and Obstetrics; Mets, metastasis; HPF, high-power field; IHC, immunohistochemistry; CK, cytokeratin; hPL, human placental lactogen; Dx, diagnostic; D/E, dilatation and evacuation; D/C/B, dilatation and curettage and biopsy; TAH, total abdominal hysterectomy; RSO, right salpingo-oophorectomy; LS, left salpingectomy; PLND, pelvic lymph node dissection; SPA-H, single port assisted laparoscopic hysterectomy; BS, bilateral salpingectomy; ROC, right ovarian cystectomy; LAVH, laparoscopic assisted vaginal hysterectomy; NED, no evidence of disease; N/A, not available in reported pathologic data.